Skip to main content
. 2019 Jan 1;9(1):20–33. doi: 10.7150/thno.28857

Figure 4.

Figure 4

(A) Time course fluorescence images of tumor-bearing mice receiving i.v. injection of POCL or POCL/FA- (0.2 mg/mL based on TPP, 100 μL per mouse). Tumor regions are indicated by white arrows. Fluorescence images were acquired for 1 s of exposure with excitation at 465 nm and emission at 640 nm. (B) Fluorescence signal intensities of the tumors in mice from A over time (*P < 0.05, **P < 0.01, ***P < 0.001; n = 3 per group). (C) Ex vivo fluorescence images and (D) corresponding fluorescence signal intensities of the dissected organs and tumors from the mice after 24 h of injection as indicated above (*P < 0.05, **P < 0.01, ***P < 0.001; n = 3 per group). (E) Biodistribution of POCL or POCL/FA- based on TPP at 24 h post-injection as indicated above (n = 3 per group). (F) Pharmacokinetics of POCL or POCL/FA- based on TPP in mice from 0 to 12 h after intravenous injection (n = 3 per group). (G) Time course chemiluminescence images of tumor-bearing mice receiving i.v. injection of POCL or POCL/FA- (0.2 mg/mL based on TPP, 100 μL per mouse). Tumor regions are indicated by white arrows. (H) Chemiluminescence signal intensities of the tumor in mice from G over time (*P < 0.05, **P < 0.01, ***P < 0.001; n = 3 per group).